Open Access<p>A Mansonone Derivative Coupled with Monoclonal Antibody 4D5-Modified Chitosan Inhibit AKR1C3 to Treat Castration-Resistant Prostate Cancer</p>
Author(s) -
Meng Zhou,
Xiaoyu Wang,
Jie Xia,
Yueming Cheng,
Lichun Xiao,
Bin Yu,
Justin Tang,
Yadong Huang,
Qi Xiang,
ShiLiang Huang
Publication year - 2020
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s241324
Subject(s) - lncap , chemistry , prostate cancer , dihydrotestosterone , androgen receptor , cancer research , testosterone (patch) , microbiology and biotechnology , endocrinology , androgen , medicine , cancer , biology , biochemistry , hormone
Aldo-ketoreductase (AKR) 1C3 is crucial for testosterone synthesis. Abnormally high expression/activity of AKR1C3 can promote castration-resistant prostate cancer (CRPC). A mansonone derivative and AKR1C3 inhibitor, 6e, was combined with 4D5 (extracellular fragment of the monoclonal antibody of human epidermal growth factor receptor-2)-modified chitosan to achieve a nanodrug-delivery system (CS-4D5/6e) to treat CRPC.